[Value of radiotherapy and chemotherapy in treatment of operable cancers of the esophagus]
- PMID: 12071024
[Value of radiotherapy and chemotherapy in treatment of operable cancers of the esophagus]
Abstract
Radiotherapy and chemotherapy have been used for more than twenty years as adjuvant treatment of operable cancer of the esophagus. The palliative effect of adjuvant (or neoadjuvant) radio- and/or chemotherapy has been demonstrated in numerous randomized trials. The purpose of this review is to present the principal randomized trials conducted in the treatment of operable cancer of the esophagus. Alone, radiotherapy does not significantly improve survival in patients with operable cancer of the esophagus, irrespective of the pre- or postoperative timing (three trials and one meta-analysis for preoperative, three trials for postoperative, and one trial for pre- and postoperative radiotherapy). Likewise, alone chemotherapy does not significantly improve survival whether given preoperatively (four trials), postoperatively (two trials) or pre- and postoperatively (one trial). Radiochemotherapy combinations appear to provide more hope, but preliminary results are insufficient to draw a clear conclusion. Nevertheless, trial comparing radiotherapy results with chemotherapy, conducted pre- or postoperatively (four trials) appear to demonstrate a significant effect of chemotherapy. The two trials using neoadjuvant therapy have been conducted on patients with adenocarcinomas of the cardia and/or the lower esophagus and have demonstrated very encouraging results for a small number of patients. Finally, the Herslovic trial, while conducted in patients who were initially inoperable, is the only one which has demonstrated superiority of radiochemotherapy over radiotherapy alone. In conclusion, there is still much room for improvement in survival using combined radio- and chemotherapy with different forms (new agents, new associations) and treatment modes (pre- and postoperative or postoperative alone). Despite the wide use of radiotherapy and chemotherapy for cancer of the esophagus, it must be recalled that surgical resection remains the method providing the best chances of survival.
Similar articles
-
Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.Gan To Kagaku Ryoho. 1999 Jan;26(1):10-40. Gan To Kagaku Ryoho. 1999. PMID: 9987495 Review.
-
[Concurrent concentrated radio-chemotherapy of epidermoid cancer of the esophagus. Long-term results of a phase II national multicenter trial in 122 non-operable patients (FFCD 8803)].Gastroenterol Clin Biol. 2000 Feb;24(2):201-10. Gastroenterol Clin Biol. 2000. PMID: 12687962 Clinical Trial. French.
-
[Should adjuvant or neoadjuvant treatment be administered in esophageal cancer?].Ann Chir. 1997;51(6):605-10. Ann Chir. 1997. PMID: 9406457 Review. French.
-
Prospective non-randomized trial comparing esophagectomy-followed-by-chemoradiotherapy versus chemoradiotherapy-followed-by-esophagectomy for T4 esophageal cancers.J Surg Oncol. 2005 Jun 15;90(4):209-19. doi: 10.1002/jso.20259. J Surg Oncol. 2005. PMID: 15906363 Clinical Trial.
-
Preoperative and adjuvant therapies for upper gastrointestinal cancers.Expert Rev Anticancer Ther. 2005 Aug;5(4):719-25. doi: 10.1586/14737140.5.4.719. Expert Rev Anticancer Ther. 2005. PMID: 16111471 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical